Literature DB >> 3498740

In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination.

R N Jones1, A L Barry, R R Packer, W W Gregory, C Thornsberry.   

Abstract

Broth microdilution tests and an antimicrobial interaction (synergy) studies using various combinations of cefoperazone and sulbactam were performed in an effort to determine the most appropriate in vitro dilution test system. The test results with cefoperazone and sulbactam were categorized as synergistic (complete or partial) for nearly 80% of the strains isolated from clinical trial patients. The results indicate that the cefoperazone-sulbactam fixed ratio (2:1) maximized the cefoperazone spectrum of activity and best approximated the parenteral formulation of the drug. The cefoperazone-sulbactam combination had a greater antimicrobial activity than did the other comparison beta-lactams, except for imipenem, tested against strains of the family Enterobacteriaceae. To be consistent with the National Committee for Clinical Laboratory Standards interpretive breakpoints for cefoperazone alone, the following MIC breakpoints should be applied to the combination (2:1 ratio): less than or equal to 16/8 micrograms/ml, susceptible; 32/16 micrograms/ml, moderately susceptible; and greater than or equal to 64/32 micrograms/ml, resistant.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498740      PMCID: PMC269316          DOI: 10.1128/jcm.25.9.1725-1729.1987

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors.

Authors:  A L Barry; R N Jones; R R Packer
Journal:  J Antimicrob Chemother       Date:  1986-01       Impact factor: 5.790

2.  Bactericidal activity of cefoperazone with CP-45,899 against large inocula of beta-lactamase-producing Haemophilus influenzae.

Authors:  P K Yu; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

3.  Synergistic activity of cefoperazone in combination with beta-lactamase inhibitors.

Authors:  K P Fu; H C Neu
Journal:  J Antimicrob Chemother       Date:  1981-03       Impact factor: 5.790

4.  In vitro activity and disk susceptibility of Timentin: current status.

Authors:  P C Fuchs; A L Barry; R N Jones
Journal:  Am J Med       Date:  1985-11-29       Impact factor: 4.965

5.  Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.

Authors:  P C Appelbaum; M R Jacobs; S K Spangler; S Yamabe
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

6.  Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.

Authors:  S C Aronoff; M R Jacobs; S Johenning; S Yamabe
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

7.  Beta-lactamase stability of cefpirome (HR 810), a new cephalosporin with a broad antimicrobial spectrum.

Authors:  S Kobayashi; S Arai; S Hayashi; K Fujimoto
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

8.  The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests.

Authors:  R N Jones; A L Barry; C Thornsberry; H W Wilson
Journal:  Am J Clin Pathol       Date:  1985-10       Impact factor: 2.493

9.  In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies.

Authors:  R N Jones; H W Wilson; C Thornsberry; A L Barry
Journal:  Diagn Microbiol Infect Dis       Date:  1985-11       Impact factor: 2.803

10.  Principal beta-lactamases responsible for resistance to beta-lactam antibiotics in urinary tract infections.

Authors:  I N Simpson; P B Harper; C H O'Callaghan
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

View more
  17 in total

1.  Error rates in cefoperazone and cefoperazone-sulbactam disk tests with Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  D J Hardy; A L Barry; P C Fuchs; E H Gerlach; J C McLaughlin; M A Pfaller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-10       Impact factor: 3.267

2.  First identification of OXA-72 carbapenemase from Acinetobacter pittii in Colombia.

Authors:  Maria Camila Montealegre; Juan José Maya; Adriana Correa; Paula Espinal; Maria F Mojica; Sory J Ruiz; Fernando Rosso; Jordi Vila; John P Quinn; Maria Virginia Villegas
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

3.  Use of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

4.  In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters.

Authors:  R J Fass; W W Gregory; R F D'Amato; J M Matsen; D N Wright; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

5.  Multiple-dose pharmacokinetics and toleration of intravenously administered cefoperazone and sulbactam when given as single agents or in combination.

Authors:  D P Reitberg; T J Whall; M Chung; D Blickens; H Swarz; J Arnold
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

6.  Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination.

Authors:  A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1988-01       Impact factor: 5.948

7.  In vitro activity of cefoperazone-sulbactam combinations against cefoperazone-resistant clinical bacterial isolates.

Authors:  G M Eliopoulos; K Klimm; M J Ferraro; R C Moellering
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

8.  Clinical epidemiology and molecular analysis of extended-spectrum-β-lactamase-producing Escherichia coli in Nepal: characteristics of sequence types 131 and 648.

Authors:  Jatan Bahadur Sherchan; Kayoko Hayakawa; Tohru Miyoshi-Akiyama; Norio Ohmagari; Teruo Kirikae; Maki Nagamatsu; Masayoshi Tojo; Hiroshi Ohara; Jeevan B Sherchand; Sarmila Tandukar
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

9.  Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.

Authors:  D P Reitberg; D A Marble; R W Schultz; T J Whall; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

10.  In vitro activities of ampicillin-sulbactam and cefoperazone-sulbactam against oxacillin-susceptible and oxacillin-resistant staphylococci.

Authors:  A L Barry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.